浙江东方基因生物制品股份有限公司第三届董事会第十六次会议决议公告

Core Viewpoint - The company has decided to terminate certain fundraising investment projects and permanently supplement the remaining funds into working capital for daily operations, which requires shareholder approval [30][31][36]. Group 1: Board Meeting Resolutions - The board meeting held on December 25, 2025, approved the proposal to terminate the "Technology Research and Development Center Construction Project" and to permanently supplement the remaining funds into working capital [2][30]. - The board also approved the establishment of a "Securities Investment Management System" [3]. - A notice for the 2026 first extraordinary shareholders' meeting was also approved [4]. Group 2: Fundraising Project Details - The company raised a total of RMB 637.5 million through its initial public offering, with a net amount of RMB 550.8 million after expenses [7][31]. - The "Marketing Network and Information Management Platform Construction Project" has reached its intended usable state, and the remaining funds will be used for daily operations [10][12]. - As of December 23, 2025, the project had a total investment of RMB 86.1655 million, with a surplus of RMB 9.5162 million [10][12]. Group 3: Reasons for Termination of Projects - The termination of the "Technology Research and Development Center Construction Project" is due to the inability to proceed with construction during the global public health crisis from 2020 to 2022, leading to a reassessment of funding needs [33][34]. - The company has utilized its own funds for the construction of the research center, which has already been completed, making further investment in the original project unnecessary [34][35]. Group 4: Shareholder Meeting Information - The 2026 first extraordinary shareholders' meeting is scheduled for January 13, 2026, and will utilize both on-site and online voting methods [14][15]. - Shareholders must register for the meeting by providing necessary documentation, and the meeting will be held at the company's headquarters [21][25].